The aim of a study carried out by Spanish researchers was to identify and analyse policies applied in the health services to enhance uptake of biosimilars in the framework of clinical management settings [1]. Incentives, both financial and non-financial, were of particular interest for the authors. They reviewed the relevant experiences developed in different high-income countries with advanced healthcare systems. In addition, they investigated barriers to the implementation of these policies in Spain.
- INICIO
-
Genéricos
Novedades
- FDA approves generic teriparatide and levetiracetam
- US generics launch and approval for Dr Reddy’s and Lupin
- Five Chinese companies join UN’s MPP for Covid-19 medicines
- South Korean companies to make generic Bridion and COVID-19 drugs
Investigación
- Japan’s drug shortage crisis: challenges and policy solutions
- Saudi FDA drug approvals and GMP inspections: trend analysis
- Generic medications in the Lebanese community: understanding and public perception
- Community pharmacists’ understanding of generic and biosimilar drugs: Lebanon case study
General
- EMA launches European shortages monitoring platform to tackle persistent medicine shortages
- Crecimiento de medicamentos genéricos en Brasil y Venezuela
- Penetración de los medicamentos genéricos en México y Brasil
- FDA releases one-year progress report for the Generic Drug Cluster
-
Biosimilares
Novedades
- EMA recommends approval of three aflibercept biosimilars: Ahzantive, Baiama, and Eydenzelt
- Canada approves first tocilizumab biosimilar Tyenne
- EMA recommends approval for ustekinumab biosimilar Absimky and Imuldosa
- Canada approves pegfilgrastim biosimilar Armlupeg
Investigación
- Comparative efficacy studies: where are we now?
- Pertuzumab biosimilar HLX11 meets primary endpoint in phase III comparative clinical study
- Perfil del biosimilar Uzpruvo/ AVT04
- Long-term real-world safety experience of biosimilars confirms concept of biosimilarity
General
- Productos biológicos y biosimilares disponibles para la EII en Canadá
- Biosimilar medicines on the Pharmaceutical Benefits Scheme in Australia
- La SBR emite consenso sobre intercambiabilidad de productos de referencia y biosimilares
- Un innovador acuerdo de compra directa permite reducir drásticamente los precios de los biosimilares de adalimumab
- MORE EDITORIAL SECTIONS
- Search
Comments (0)
Post your comment